Innoviva Other Long-Term Assets 2010-2024 | INVA
Innoviva other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Innoviva Annual Other Long-Term Assets
(Millions of US $) |
| 2023 |
$3 |
| 2022 |
$4 |
| 2021 |
$0 |
| 2020 |
$0 |
| 2019 |
$0 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$0 |
| 2014 |
$18 |
| 2013 |
$8 |
| 2012 |
$3 |
| 2011 |
$3 |
| 2010 |
$4 |
| 2009 |
$5 |
Innoviva Quarterly Other Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$3 |
| 2024-03-31 |
$3 |
| 2023-12-31 |
$3 |
| 2023-09-30 |
$3 |
| 2023-06-30 |
$4 |
| 2023-03-31 |
$4 |
| 2022-12-31 |
$4 |
| 2022-09-30 |
$5 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$0 |
| 2021-12-31 |
$0 |
| 2021-09-30 |
$0 |
| 2021-06-30 |
$0 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
$0 |
| 2019-09-30 |
$0 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
$0 |
| 2018-09-30 |
$0 |
| 2018-06-30 |
$0 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$0 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$0 |
| 2015-09-30 |
$16 |
| 2015-06-30 |
$17 |
| 2015-03-31 |
$17 |
| 2014-12-31 |
$18 |
| 2014-09-30 |
$21 |
| 2014-06-30 |
$23 |
| 2014-03-31 |
$9 |
| 2013-12-31 |
$8 |
| 2013-09-30 |
$7 |
| 2013-06-30 |
$8 |
| 2013-03-31 |
$9 |
| 2012-12-31 |
$3 |
| 2012-09-30 |
$3 |
| 2012-06-30 |
$3 |
| 2012-03-31 |
$3 |
| 2011-12-31 |
$3 |
| 2011-09-30 |
$4 |
| 2011-06-30 |
$4 |
| 2011-03-31 |
$4 |
| 2010-12-31 |
$4 |
| 2010-09-30 |
$4 |
| 2010-06-30 |
$5 |
| 2010-03-31 |
$5 |
| 2009-12-31 |
$5 |
| 2009-09-30 |
$6 |
| 2009-06-30 |
$6 |
| 2009-03-31 |
$9 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.259B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
